search
Back to results

Oral Probiotics on the Microbiome and Lipidome in Acne Vulgaris

Primary Purpose

Acne Vulgaris

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Probiotic
Placebo
Sponsored by
Integrative Skin Science and Research
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acne Vulgaris focused on measuring acne vulgaris, skin, dermatology, acne, microbiome, probiotics

Eligibility Criteria

13 Years - 45 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Subjects aged 13-45
  • Subjects with acne vulgaris as diagnosed by a board-certified dermatologist,having mild-moderate acne on the face with an IGA score of 2-3 and 10+ inflammatory lesions on face and 15+ total lesions.
  • Subjects should experience new acne lesions on a recurrent basis within last 6 months
  • Must be willing to comply with all protocol requirements
  • Must be willing to have flash photo facial images taken with the imaging systems
  • Males must be willing to shave any facial hair

Exclusion Criteria:

  • Any systemic antibiotics used to treat acne (injected or oral)within 6 months of starting study. Any 14-day or shorter course of systemic antibiotics (injected or oral) used to treat conditions other than acne within 1 month of starting study
  • Any topical antibiotic or benzoyl peroxide within 1 month of starting study or any subject unwilling to refrain from washout of topical antibacterial or benzoyl peroxide ingredient.
  • Any oral probiotic or prebiotic supplementation within past 1 month
  • Subjects must have no history of malignancy or cancer or diagnosis of gastrointestinal inflammatory diseases, no history or diagnosis of epilepsy, no history or diagnosis of immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus, rheumatoid arthritis)
  • Has a condition or is on medication the investigator and/or designee believe could jeopardize the safety of the subject, interfere with the evaluation, or confound the interpretation of the study results
  • Women who have been pregnant in the last three months, are pregnant, preparing to be pregnant or lactating, or post-menopausal.
  • Is participating in a concurrent clinical research study or has participated in acne or other facial study at this or any other facility in the past 4 weeks
  • Those with BMI higher than 35kg/m²
  • Those that have undergone a change in hormonally based therapies, such as but not limited to oral contraceptive pills or progesterone based pills within the last two months. Progesterone releasing IUDs and spironolactone are considered hormone-based therapy.
  • Commencement of a new diet (such as the ketogenic diet)or supplements within the 1 month prior to initiating participation, at the discretion of the investigator.
  • Use of medications that alter blood lipids, such as statins and anti-hyperlipidemic medications
  • Is participating in or has participated in acne or other facial study at this or any other facility in the past 4 weeks. Participation in survey-based studies are approved at the discretion of the investigator.
  • Has a skin disease on face, other than acne, that will interfere with image collection and assessment in the opinion of the investigator
  • Refusal to shave or remove facial hair that may interfere with image collection and assessment.
  • Severe acne or nodulocystic acne, at the discretion of the investigator
  • Use of isotretinoin within the 6 months prior to starting in study.
  • Persons unwilling to avoid the following during the 4 weeks prior and during the duration of the study: self-tanning, spa tanning, or artificial tanning.
  • Known allergy or irritation to the supplement or facial products utilized in the study
  • Current tobacco smokers, OR those that have smoked tobacco over the past year, OR a 5 year-pack year history of smoking tobacco
  • Prisoners
  • Adults unable to consent

Sites / Locations

  • Integrative Skin Science and ResearchRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo

Probiotic

Arm Description

Participants will be taking a placebo supplement that they will be taking by mouth once per day.

Participants will be taking a probiotic supplement that they will be taking by mouth once per day.

Outcomes

Primary Outcome Measures

Microbiota Diversity
Evaluation of alpha diversity
Short chain fatty acids
Blood plasma
Blood acetate levels
Blood plasma

Secondary Outcome Measures

Gut microbiome changes
Evaluation of alpha diversity
Change in skin microbiome
Relative abundance cutibacterium genera
Safety assessments for GI distress
Self assessment using Digestive Questionnaire
Change in sebum excretion rate
Sebumeter: 0-150 micrograms/cm^2
Change in skin hydration
Moisturemeter: 0-150
Change in skin pH
Use of pH meter
Facial redness - Image based
BTBP Clarity Mini 3D camera
Facial skin tone - Image based
BTBP Clarity Mini 3D camera
Subjective assessment of the skin
Self-assessment through Dermatology Quality of Life questionnaire
Safety assessment of acne
Evaluation of acne to assess for flares
Gut Microbiome Changes
Relative abundance of Akkermansia muciniphila

Full Information

First Posted
October 9, 2020
Last Updated
November 20, 2020
Sponsor
Integrative Skin Science and Research
Collaborators
Microbiome labs
search

1. Study Identification

Unique Protocol Identification Number
NCT04596748
Brief Title
Oral Probiotics on the Microbiome and Lipidome in Acne Vulgaris
Official Title
Prospective Randomized Double-Blind Placebo-Controlled Study of Oral Probiotics on the Microbiome and Lipidome in Acne Vulgaris
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Unknown status
Study Start Date
May 11, 2020 (Actual)
Primary Completion Date
March 2021 (Anticipated)
Study Completion Date
March 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Integrative Skin Science and Research
Collaborators
Microbiome labs

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine how probiotics affect sebum production and gut health in those with acne vulgaris.
Detailed Description
Probiotics have been shown in previous pilot studies to be helpful in acne and this study aims to examine how the gut microbiome and skin biophysical properties are shifted in those with acne vulgaris. In particular, this study will assess the influence of oral spore based probiotics on the skin sebum production and will assess how probiotics influence the gut microbiome and the blood levels of short chain fatty acids.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acne Vulgaris
Keywords
acne vulgaris, skin, dermatology, acne, microbiome, probiotics

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Double-blind, randomized, placebo-controlled
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
70 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will be taking a placebo supplement that they will be taking by mouth once per day.
Arm Title
Probiotic
Arm Type
Experimental
Arm Description
Participants will be taking a probiotic supplement that they will be taking by mouth once per day.
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotic
Intervention Description
Bacillus Subtilis, Bacillus Clausii, Bacillus Coagulans, Bacillus Indicus HU36, MCC 102
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Placebo caps
Primary Outcome Measure Information:
Title
Microbiota Diversity
Description
Evaluation of alpha diversity
Time Frame
12 weeks
Title
Short chain fatty acids
Description
Blood plasma
Time Frame
12 weeks
Title
Blood acetate levels
Description
Blood plasma
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Gut microbiome changes
Description
Evaluation of alpha diversity
Time Frame
4 weeks and 8 weeks
Title
Change in skin microbiome
Description
Relative abundance cutibacterium genera
Time Frame
12 weeks
Title
Safety assessments for GI distress
Description
Self assessment using Digestive Questionnaire
Time Frame
4 weeks, 8 weeks, 12 weeks
Title
Change in sebum excretion rate
Description
Sebumeter: 0-150 micrograms/cm^2
Time Frame
4 weeks, 8 weeks, 12 weeks
Title
Change in skin hydration
Description
Moisturemeter: 0-150
Time Frame
4,8 and 12 weeks
Title
Change in skin pH
Description
Use of pH meter
Time Frame
4,8, and 12 weeks
Title
Facial redness - Image based
Description
BTBP Clarity Mini 3D camera
Time Frame
4,8,12 weeks
Title
Facial skin tone - Image based
Description
BTBP Clarity Mini 3D camera
Time Frame
4,8,12 weeks
Title
Subjective assessment of the skin
Description
Self-assessment through Dermatology Quality of Life questionnaire
Time Frame
4,8,12 weeks
Title
Safety assessment of acne
Description
Evaluation of acne to assess for flares
Time Frame
4, 8, 12 weeks
Title
Gut Microbiome Changes
Description
Relative abundance of Akkermansia muciniphila
Time Frame
4, 8, 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
13 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subjects aged 13-45 Subjects with acne vulgaris as diagnosed by a board-certified dermatologist,having mild-moderate acne on the face with an IGA score of 2-3 and 10+ inflammatory lesions on face and 15+ total lesions. Subjects should experience new acne lesions on a recurrent basis within last 6 months Must be willing to comply with all protocol requirements Must be willing to have flash photo facial images taken with the imaging systems Males must be willing to shave any facial hair Exclusion Criteria: Any systemic antibiotics used to treat acne (injected or oral)within 6 months of starting study. Any 14-day or shorter course of systemic antibiotics (injected or oral) used to treat conditions other than acne within 1 month of starting study Any topical antibiotic or benzoyl peroxide within 1 month of starting study or any subject unwilling to refrain from washout of topical antibacterial or benzoyl peroxide ingredient. Any oral probiotic or prebiotic supplementation within past 1 month Subjects must have no history of malignancy or cancer or diagnosis of gastrointestinal inflammatory diseases, no history or diagnosis of epilepsy, no history or diagnosis of immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus, rheumatoid arthritis) Has a condition or is on medication the investigator and/or designee believe could jeopardize the safety of the subject, interfere with the evaluation, or confound the interpretation of the study results Women who have been pregnant in the last three months, are pregnant, preparing to be pregnant or lactating, or post-menopausal. Is participating in a concurrent clinical research study or has participated in acne or other facial study at this or any other facility in the past 4 weeks Those with BMI higher than 35kg/m² Those that have undergone a change in hormonally based therapies, such as but not limited to oral contraceptive pills or progesterone based pills within the last two months. Progesterone releasing IUDs and spironolactone are considered hormone-based therapy. Commencement of a new diet (such as the ketogenic diet)or supplements within the 1 month prior to initiating participation, at the discretion of the investigator. Use of medications that alter blood lipids, such as statins and anti-hyperlipidemic medications Is participating in or has participated in acne or other facial study at this or any other facility in the past 4 weeks. Participation in survey-based studies are approved at the discretion of the investigator. Has a skin disease on face, other than acne, that will interfere with image collection and assessment in the opinion of the investigator Refusal to shave or remove facial hair that may interfere with image collection and assessment. Severe acne or nodulocystic acne, at the discretion of the investigator Use of isotretinoin within the 6 months prior to starting in study. Persons unwilling to avoid the following during the 4 weeks prior and during the duration of the study: self-tanning, spa tanning, or artificial tanning. Known allergy or irritation to the supplement or facial products utilized in the study Current tobacco smokers, OR those that have smoked tobacco over the past year, OR a 5 year-pack year history of smoking tobacco Prisoners Adults unable to consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Raja K Sivamani, MD
Phone
916-524-1216
Email
raja.sivamani@integrativeskinresearch.com
Facility Information:
Facility Name
Integrative Skin Science and Research
City
Sacramento
State/Province
California
ZIP/Postal Code
95815
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Raja K Sivamani, MD
Phone
916-524-1216
Email
raja.sivamani@integrativeskinresearch.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Oral Probiotics on the Microbiome and Lipidome in Acne Vulgaris

We'll reach out to this number within 24 hrs